Axon Seeks Partner For Alzheimer’s Vaccine After Finishing Phase II Trial
Executive Summary
The Slovakian biotech thinks “positive signals” and “compelling trends” seen in the trial of patients with mild Alzheimer’s support further development, leading it to begin a search for a global partner.